Unjha Formulations share price, P/E, ROE & financials

As of 6 Nov 2026, Unjha Formulations trades at 26.2× trailing earnings, below the industry P/E of 28.7×, and the shares are 24% below their 52-week high. Sales and net profit grew 5.8% and 36% a year over 3 years; its ROCE of 25% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It is a small-cap company with a market cap of ₹12 Cr, ranked 147th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 26% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹30.38
Day high: ₹30.38
Day low: ₹27.55
Prev. close: ₹28.99
Volume: 3.2K

Health check

1 good · 4 fair · 1 to check

ReturnsIn line
+26.0% over a year, better than 4 of 7 peers.
Price tagIn line
P/E 26.2 vs industry 28.7.
GrowthSteady
Sales +5.8%, profit +35.6% a year over 3 years.
ProfitabilityStrong
ROCE 24.8% vs peer median 17.9%.
Balance sheetFair
Piotroski 7 of 9.
Red flags2 to check
Quarterly profit down 59.8% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹12 Cr, #147 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹15 Cr · profit ₹0 Cr

Market cap: ₹12 Cr; Small cap
P/E: 26.2; Industry 28.7
Price to book: 3.21; Peers 4.99
Dividend yield: 0.00%
ROE: 20.2%; Peers 14.7%
ROCE: 24.8%; Peers 17.9%
Debt to equity: n/a; Debt ₹0.00 Cr
EPS (TTM): ₹1.05
OPM (TTM): 5.3%; Net margin 3.1%
Sales growth: −8.5%; Latest quarter vs a year ago
Profit growth: −59.8%; Latest quarter vs a year ago
Price to sales: 0.81; EV/EBITDA 14.3

Strengths

Return on equity of 20.2%.
Return on capital employed of 24.8%.

Risks to check

Quarterly profit down 59.8% on a year ago.
Quarterly sales down 8.5% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About Unjha Formulations

Unjha Formulations Limited manufactures and sells ayurvedic products in India. The company offers sat-isabgol and isabgo husk formulation in elaichi flavor under the Anchor name; and isabgol powder in orange flavor under the Fibron, Fibron SF and Fibron SF (Sugar Free) names. It also exports its products. Unjha Formulations Limited was incorporated in 1994 and is based in Sidhpur, India.

Headquarters: Sidhpur
Employees: 15
Sector: Healthcare
ISIN: INE576D01015
Website: unjhaformulations.com

Price range

52 weeks

₹17.52₹36.38

Today

₹27.55₹30.38

Avg volume (3M): 5K
1-year return: plus 26.0%
From 52-week high: minus 24.3%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
UNJHAFORUnjha Formulations	27.55	minus 4.97%	12	26.2	3.21	24.8%	20.2%	5.3%	5.8%	35.6%	0.00%	plus 26.0%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
3.6	4.3	4.4	3.3	3.3
3.2	3.5	4.1	3.7	3.1
0.4	0.8	0.3	−0.4	0.2
11.6%	18.3%	6.4%	−13.6%	5.9%
0	0.1	0	0	0
0	0	0	0	0
0	0	0	0	0
0.4	0.8	0.2	−0.5	0.2
–	–	–	−50.5%	–
0.4	0.8	0.2	−0.7	0.2
0.87	1.83	0.53	-1.66	0.35

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +5.8%
Profit CAGR 3Y: +35.6%
EPS CAGR 3Y: +35.6%
ROE: 20.2%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
13.2	18.5	13.9	15.6
–	+40.6%	minus 25.1%	+12.4%
12.7	17.9	13.3	14.6
0.4	0.6	0.5	0.9
3.3%	3.1%	3.7%	6.0%
0	0	0.1	0.2
0	0.1	0	0
0.1	0.1	0.1	0.1
–	–	0	–
0.3	0.5	0.5	1
14.3%	38.5%	22.2%	26.1%
0.3	0.3	0.4	0.7
–	minus 1.6%	+46.6%	+72.9%
0.63	0.62	0.91	1.57

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
4.5	4.5	4.5	4.5
−2	−1.7	−1.3	−0.6
1	2.2	1.4	1.7
3.4	4.9	4.6	5.5
0.6	0.6	0.7	0.8
0	0.9	0.6	1.6
2.8	3.4	3.2	3.1
3.4	4.9	4.6	5.5

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−0.3	1	−0	1.2
−0.1	−0.1	−0.2	−0.2
−0.1	−0.1	−0	−0
−0.4	0.9	−0.2	1
−0.1	−0.1	−0.2	−0.2
−0.4	0.9	−0.2	1

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you